689 related articles for article (PubMed ID: 27637004)
1. A Critical Evaluation of Anti-IL-13 and Anti-IL-4 Strategies in Severe Asthma.
Bagnasco D; Ferrando M; Varricchi G; Passalacqua G; Canonica GW
Int Arch Allergy Immunol; 2016; 170(2):122-31. PubMed ID: 27637004
[TBL] [Abstract][Full Text] [Related]
2. Targeting the interleukin-4 and interleukin-13 pathways in severe asthma: current knowledge and future needs.
Parulekar AD; Kao CC; Diamant Z; Hanania NA
Curr Opin Pulm Med; 2018 Jan; 24(1):50-55. PubMed ID: 29036019
[TBL] [Abstract][Full Text] [Related]
3. Monoclonal antibodies for the treatment of refractory asthma.
Hambly N; Nair P
Curr Opin Pulm Med; 2014 Jan; 20(1):87-94. PubMed ID: 24275927
[TBL] [Abstract][Full Text] [Related]
4. [Inflammatory cytokines (IL-4, IL-5 and IL-13)].
Maeda S; Yanagihara Y
Nihon Rinsho; 2001 Oct; 59(10):1894-9. PubMed ID: 11676128
[TBL] [Abstract][Full Text] [Related]
5. Characterization of asthma endotypes: implications for therapy.
Stokes JR; Casale TB
Ann Allergy Asthma Immunol; 2016 Aug; 117(2):121-5. PubMed ID: 27499539
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-4/interleukin-13 versus interleukin-5: a comparison of molecular targets in biologic therapy for the treatment of severe asthma.
Wu AY; Sur S; Grant JA; Tripple JW
Curr Opin Allergy Clin Immunol; 2019 Feb; 19(1):30-37. PubMed ID: 30407206
[TBL] [Abstract][Full Text] [Related]
7. Role of periostin, FENO, IL-13, lebrikzumab, other IL-13 antagonist and dual IL-4/IL-13 antagonist in asthma.
Agrawal S; Townley RG
Expert Opin Biol Ther; 2014 Feb; 14(2):165-81. PubMed ID: 24283478
[TBL] [Abstract][Full Text] [Related]
8. Biologic and New Therapies in Asthma.
Tabatabaian F; Ledford DK; Casale TB
Immunol Allergy Clin North Am; 2017 May; 37(2):329-343. PubMed ID: 28366480
[TBL] [Abstract][Full Text] [Related]
9. IL-13 and the IL-13 receptor as therapeutic targets for asthma and allergic disease.
Mitchell J; Dimov V; Townley RG
Curr Opin Investig Drugs; 2010 May; 11(5):527-34. PubMed ID: 20419598
[TBL] [Abstract][Full Text] [Related]
10. Biological treatments for severe asthma: A major advance in asthma care.
Busse WW
Allergol Int; 2019 Apr; 68(2):158-166. PubMed ID: 30792118
[TBL] [Abstract][Full Text] [Related]
11. Lebrikizumab for the treatment of asthma.
Antoniu SA
Expert Opin Investig Drugs; 2016 Oct; 25(10):1239-49. PubMed ID: 27554950
[TBL] [Abstract][Full Text] [Related]
12. Targeted anti-IL-13 therapies in asthma: current data and future perspectives.
Ntontsi P; Papathanassiou E; Loukides S; Bakakos P; Hillas G
Expert Opin Investig Drugs; 2018 Feb; 27(2):179-186. PubMed ID: 29334288
[TBL] [Abstract][Full Text] [Related]
13. The effects of lebrikizumab in patients with mild asthma following whole lung allergen challenge.
Scheerens H; Arron JR; Zheng Y; Putnam WS; Erickson RW; Choy DF; Harris JM; Lee J; Jarjour NN; Matthews JG
Clin Exp Allergy; 2014 Jan; 44(1):38-46. PubMed ID: 24131304
[TBL] [Abstract][Full Text] [Related]
14. Preclinical efficacy and safety of pascolizumab (SB 240683): a humanized anti-interleukin-4 antibody with therapeutic potential in asthma.
Hart TK; Blackburn MN; Brigham-Burke M; Dede K; Al-Mahdi N; Zia-Amirhosseini P; Cook RM
Clin Exp Immunol; 2002 Oct; 130(1):93-100. PubMed ID: 12296858
[TBL] [Abstract][Full Text] [Related]
15. Dupilumab for the treatment of asthma.
Santini G; Mores N; Malerba M; Mondino C; Anzivino R; Macis G; Montuschi P
Expert Opin Investig Drugs; 2017 Mar; 26(3):357-366. PubMed ID: 28085503
[TBL] [Abstract][Full Text] [Related]
16. Choice of biologics in asthma endotypes.
Wangberg H; Woessner K
Curr Opin Allergy Clin Immunol; 2021 Feb; 21(1):79-85. PubMed ID: 33306486
[TBL] [Abstract][Full Text] [Related]
17. Novel Biomarkers in Severe Asthma.
Zervas E; Samitas K; Gaga M
Arch Bronconeumol; 2017 Apr; 53(4):175-176. PubMed ID: 28283213
[No Abstract] [Full Text] [Related]
18. Asthma phenotyping: a necessity for improved therapeutic precision and new targeted therapies.
Chung KF
J Intern Med; 2016 Feb; 279(2):192-204. PubMed ID: 26076339
[TBL] [Abstract][Full Text] [Related]
19. A randomized, placebo-controlled trial evaluating effects of lebrikizumab on airway eosinophilic inflammation and remodelling in uncontrolled asthma (CLAVIER).
Austin CD; Gonzalez Edick M; Ferrando RE; Solon M; Baca M; Mesh K; Bradding P; Gauvreau GM; Sumino K; FitzGerald JM; Israel E; Bjermer L; Bourdin A; Arron JR; Choy DF; Olsson JK; Abreu F; Howard M; Wong K; Cai F; Peng K; Putnam WS; Holweg CTJ; Matthews JG; Kraft M; Woodruff PG;
Clin Exp Allergy; 2020 Dec; 50(12):1342-1351. PubMed ID: 32909660
[TBL] [Abstract][Full Text] [Related]
20. New Anti-Eosinophil Drugs for Asthma and COPD: Targeting the Trait!
Bel EH; Ten Brinke A
Chest; 2017 Dec; 152(6):1276-1282. PubMed ID: 28583618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
